Sort   by:  
 Page size 
UnknownBrentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Not available
S-EPMC4171358 | biostudies-literature
UnknownLow CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.
Not available
S-EPMC9817934 | biostudies-literature
UnknownPhase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Not available
S-EPMC3833210 | biostudies-literature
UnknownAntitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
Not available
S-EPMC5348028 | biostudies-literature
UnknownA TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
Not available
S-EPMC5508079 | biostudies-literature
UnknownFive-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Not available
S-EPMC5946765 | biostudies-literature
UnknownThe ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Not available
S-EPMC9447792 | biostudies-literature
UnknownBrentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Not available
S-EPMC6436818 | biostudies-literature
UnknownP1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032
Not available
S-EPMC10430937 | biostudies-literature
UnknownHypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.
Not available
S-EPMC10219458 | biostudies-literature
Sort   by:  
 Page size